Announcement

Collapse
No announcement yet.

Diabetes Res Clin Pract . Clinical features of patients with type 2 diabetes with and without Covid-19: a case control study (CoViDiab I)

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Diabetes Res Clin Pract . Clinical features of patients with type 2 diabetes with and without Covid-19: a case control study (CoViDiab I)


    Diabetes Res Clin Pract


    . 2020 Sep 21;108454.
    doi: 10.1016/j.diabres.2020.108454. Online ahead of print.
    Clinical features of patients with type 2 diabetes with and without Covid-19: a case control study (CoViDiab I)


    Ernesto Maddaloni 1 , Luca D'Onofrio 1 , Francesco Alessandri 1 , Carmen Mignogna 1 , Gaetano Leto 2 , Lucia Coraggio 1 , Sara Sterpetti 1 , Giuseppe Pascarella 3 , Ivano Mezzaroma 1 , Miriam Lichtner 2 , Paolo Pozzilli 3 , Felice Eugenio Agrņ 3 , Monica Rocco 4 , Francesco Pugliese 1 , Claudio Maria Mastroianni 1 , Raffaella Buzzetti 5 , CoViDiab Study group



    Affiliations

    Abstract

    Aims: To evaluate whether subjects with diabetes hospitalized for Coronavirus disease-19 (Covid-19) represent a subgroup of patients with high-risk clinical features compared to patients with diabetes without Covid-19.
    Methods: In this case-control study 79 patients with type 2 diabetes out of 354 adults hospitalized for Covid-19 and 158 controls with type 2 diabetes but without Covid-19, matched for age and gender, were enrolled. Medical history and concomitant therapies were retrieved from medical charts and compared between cases and controls, controlling for confounders.
    Results: Fully-adjusted multivariate logistic regression model showed that previous CVD history did not differ between patients with and without Covid-19 (odds ratio 1.40, 95% confidence interval [CI]: 0.59-3.32, p=0.45). A higher prevalence of chronic obstructive pulmonary disease (COPD) (OR 3.72, 95%CI: 1.42-9.72, p=0.007) and of chronic kidney disease (CKD) (OR 3.08, 95%CI: 1.18-8.06, p=0.022) and a lower prevalence of ever smokers (OR 0.30, 95%CI: 0.13-0.67, p=0.003), of users of lipid lowering agents (OR 0.26, 95%CI: 0.12-0.54, p<0.001), and of anti-hypertensive drugs (OR 0.39, 95%CI: 0.16-0.93, p=0.033) were found among cases.
    Conclusions: CVD prevalence does not differ between people with diabetes with and without Covid-19 requiring hospitalization. An increased prevalence of COPD and of CKD in Covid-19 patients with type 2 diabetes is suggested. These findings aid to clarify the relationship between underlying conditions and SARS-CoV-2 infection in the high-risk group of patients with diabetes.

    Keywords: Covid-19; Diabetes; SARS-CoV-2.

Working...
X